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abstract
PURPOSE In the phase 3 KEYNOTE-407 study, the addition of pembrolizumab to carboplatin-paclitaxel/
nab-paclitaxel significantly improved overall survival, progression-free survival, and objective response
rate in patients with previously untreated metastatic squamous non–small-cell lung cancer (NSCLC), with
little impact on severe toxicity. We present patient-reported outcomes (PROs) from KEYNOTE-407.
METHODS Patients were randomly assigned to receive 4 cycles of pembrolizumab 200mg or placebo once every
3 weeks plus carboplatin plus paclitaxel or nab-paclitaxel, followed by pembrolizumab or placebo for an
additional 31 cycles. Health-related quality of life (HRQoL) was evaluated using the European Organisation for
Research and Treatment of Cancer Treatment of Cancer Quality of Life Questionnaire-Core 30 (QLQ-C30) and
Quality of Life Questionnaire-Lung Cancer Module 13 (QLQ-LC13). Key PRO endpoints were change from
baseline to weeks 9 and 18 (during and after platinum therapy) in the QLQ-C30 global health status/quality of life
(GHS/QoL) score and time to deterioration in the composite endpoint of cough, chest pain, or dyspnea from the
QLQ-C30 and QLQ-LC13. Two-sided, nominal P values are provided.
RESULTS A total of 554 and 553 patients completed$ 1 QLQ-C30 or $ 1 QLQ-LC13 assessment, respectively.
GHS/QoL score improved for the pembrolizumab-combination group (least squares [LS] mean [95% CI] change
from baseline: week 9, 1.8 [20.9 to 4.4]; week 18, 4.3 [1.7 to 6.9]) and deteriorated in the placebo-combination
group (week 9,21.8 [24.4 to 0.7]; week 18,20.57 [23.3 to 2.2]). Between-group differences were improved
for the pembrolizumab-combination group (difference in LS mean scores: week 9, 3.6 [95% CI, 0.3 to 6.9],
nominal P = .0337; week 18, 4.9 [1.4 to 8.3], nominal P = .0060). Median time to deterioration in cough, chest
pain, or dyspnea was not reached in either group (hazard ratio, 0.79; 95% CI, 0.58 to 1.06]; nominal P = .125).
CONCLUSION Addition of pembrolizumab to chemotherapy maintained or improved HRQoL measurements
relative to baseline and improved HRQoL versus chemotherapy alone at weeks 9 and 18. These results support
use of pembrolizumab plus chemotherapy as first-line therapy for metastatic squamous NSCLC.
J Clin Oncol 37. © 2019 by American Society of Clinical Oncology
INTRODUCTION
For patients with metastatic squamous non–small-cell
lung cancer (NSCLC), first-line therapy has typically
comprised platinum-taxane chemotherapy.1 KEYNOTE-
407 (ClinicalTrials.gov identifier: NCT02775435) is
a randomized phase 3 study of pembrolizumab plus
carboplatin-paclitaxel/nab-paclitaxel versus placebo
plus carboplatin-paclitaxel/nab-paclitaxel among pa-
tients with metastatic squamous NSCLC. Addition of
pembrolizumab to carboplatin-paclitaxel/nab-paclitaxel
improved overall survival (OS; hazard ratio [HR], 0.64;
95% CI, 0.49 to 0.85; P , .001) and progression-free
survival (PFS; HR, 0.56; 95% CI, 0.45 to 0.70; P ,
.001) regardless of programmed death-ligand 1 (PD-
L1) expression.2 Incidence and severity of adverse
events (AEs) were similar between groups, although
the rate of discontinuation due to AEs was higher in the
pembrolizumab-combination group versus the placebo-
combination group.
Disease-related symptoms associated with advanced
NSCLC are associated with poor health-related quality
of life (HRQoL).3,4 Two phase 3 clinical studies of
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pembrolizumab as first-line NSCLC treatment have eval-
uated changes from baseline in HRQoL and time to de-
terioration in lung cancer symptoms as prespecified
exploratory endpoints. In KEYNOTE-024 (ClinicalTrials.gov
identifier: NCT02142738), pembrolizumab monotherapy
improved OS and PFS versus platinum-based chemo-
therapy among patients with previously untreated meta-
static NSCLC (any histology; no sensitizing EGFR/ALK
alterations) with PD-L1 tumor proportion score (TPS)
$ 50%.5 Patients who received pembrolizumab also had
better global health status/quality of life (GHS/QoL) scores
and prolonged time to deterioration in lung cancer symp-
toms versus those who received chemotherapy.6 In
KEYNOTE-189 (ClinicalTrials.gov identifier: NCT03950674),
pembrolizumab plus pemetrexed-platinum improved OS
and PFS and maintained HRQoL, with improved HRQoL
over placebo plus pemetrexed-platinum after completion
of platinum therapy among patients with metastatic
nonsquamous NSCLC without sensitizing EGFR/ALK
alterations.7
We report patient-reported outcomes (PROs) from
KEYNOTE-407, which were evaluated as prespecified ex-
ploratory endpoints. These analyses evaluated changes
from baseline in GHS/QoL and time to deterioration in lung
cancer symptoms.
METHODS
Study Design and Participants
KEYNOTE-407 study design and inclusion/exclusion cri-
teria are published elsewhere.2 Briefly, eligible patients
were $ 18 years of age with histologically/cytologically
confirmed stage IV squamous NSCLC without prior sys-
temic treatment of metastatic NSCLC. The study protocol
was approved by an independent institutional review board/
ethics review committee at each site.
Patients were randomly assigned 1:1 to receive four
3-week cycles of either pembrolizumab 200 mg or saline
placebo (day 1 of each cycle) plus carboplatin area under
the curve 6 mg/mL/min (day 1) and paclitaxel 200 mg/m2
(day 1) or nab-paclitaxel 100 mg/m2 (days 1, 8, 15) at the
investigator’s discretion. Patients received pem-
brolizumab 200 mg or placebo once every 3 weeks for up
to 35 total cycles (approximately 2 years of treatment in
total). Randomization was stratified by chemotherapy
regimen (paclitaxel/nab-paclitaxel), PD-L1 expression (TPS
$ 1%/TPS , 1%; patients without an evaluable TPS
were included in the TPS , 1% group), and region (East
Asia/non‒East Asia). Treatment was discontinued on
disease progression by local radiologic review per
immune-related Response Evaluation Criteria in Solid
Tumors (irRECIST), unacceptable toxicity, intercurrent
illness preventing further treatment, or patient/investigator
decision. Patients with disease progression per RECIST
version 1.1, verified by blinded independent central
review (BICR), had their treatment assignment unblinded,
and those initially in the placebo-combination group could
cross over to receive pembrolizumab monotherapy
for up to 35 cycles. Patients in the pembrolizumab-
combination group who had documented disease pro-
gression but were benefiting clinically could receive open-
label pembrolizumab monotherapy for up to 35 total
administrations.
Endpoints
The primary endpoints were OS and PFS per RECIST
version 1.1 by BICR. Secondary endpoints included safety
and objective response rate per RECIST version 1.1 by
BICR. PROs were evaluated as prespecified exploratory
endpoints. HRQoL changes from baseline were evaluated
using the European Organisation for Research and
Treatment of Cancer (EORTC) Quality of Life Questionnaire-
Core 30 (QLQ-C30),8 Quality of Life Questionnaire-Lung
Cancer Module 13 (QLQ-LC13),9 and EuroQoL (EQ)-5D-3L.
The EQ-5D-3L was collected to generate utility values for
health states required for cost-effectiveness modeling.10
Key PRO endpoints were mean score change from base-
line to weeks 9 and 18 evaluated by the EORTC QLQ-C30
GHS/QoL and time to deterioration in the composite end-
point of cough (LC13, question 1), chest pain (LC13,
question 10), or dyspnea (C30, question 8). Supportive
PRO endpoints included mean score changes from
baseline in EORTC QLQ-C30 and EORTC QLQ-LC13
subscales, and number and proportion of patients who
were “improved,” “stable,” or “deteriorated” from baseline
at weeks 9 and 18. These time points were selected to
represent times during (week 9) and after (week 18)
chemotherapy treatment and minimize data loss due to
disease progression/death. Patients’ postbaseline PRO
scores were classified as improved, stable, or deteriorated
according to a $ 10-point change for each instrument/
scale. A score change of $ 10 points from baseline was
used to classify the change as improved or deteriorated;
this magnitude is generally accepted by patients as being
clinically meaningful.11 Effect of disease progression and
treatment on mean change from baseline to weeks 9 and
18 in QLQ-C30 GHS/QoL score was evaluated as a sup-
portive analysis.
HRQoL Assessments
Questionnaires were administered by trained study-site
personnel and completed using a tablet computer by
each patient before drug administration, AE evaluation, and
disease status notification at cycles 1-7 and every third
cycle thereafter up to 48 weeks while on treatment and at
treatment discontinuation and 30-day safety follow-up
visits. Instruments were administered in the following or-
der: EQ-5D-3L, EORTC QLQ-C30, and EORTC QLQ-LC13.
Statistical Analyses
Planned enrollment was 560 patients. Assuming 361
deaths, this provided approximately 85% power to detect an
2 © 2019 by American Society of Clinical Oncology
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HR of 0.7 with an alpha of .01 (1 sided). Power calculations
were not performed for PRO analyses; P values for all PRO
analyses were 2 sided and nominal. There was no adjust-
ment for multiplicity.
PROs were analyzed in the full-analysis population (all
randomly assigned patients who received $ 1 dose of
study treatment and completed $ 1 PRO assessment).
Patients who completed $ 1 item on a PRO instrument
were considered to have completed $ 1 PRO assess-
ment. The completion rate was the percentage of pa-
tients who completed $ 1 PRO assessment in the full-
analysis population at each time point. Compliance with
PRO assessment was defined as the proportion of pa-
tients who completed $ 1 item among those who were
expected to complete the questionnaires (ie, those who
were alive, had not discontinued, had translation avail-
able, and had a scheduled visit).
Evaluation of mean change from baseline to weeks 9 and
18 in the PRO instrument score was based on a con-
strained longitudinal data analysis model (Data Sup-
plement). The response variable was the PRO score, and
the covariates were treatment by study visit and ran-
domization stratification factors. Between-group com-
parisons were reported as differences in the least
PRO analysis population
   QLQ-C30    (n = 276)
   QLQ-LC13    (n = 275)
PRO analysis population
   QLQ-C30    (n = 278)
   QLQ-LC13    (n = 278)
Discontinued         (n = 208) 
PD       (n = 166)
AEs          (n = 25)
          (n = 9)
  (n = 6)
    (n = 2)
Discontinued                (n = 157)         
PD        (n = 99)
AEs              (n = 48) 
Withdrew              (n = 5)
Physician decision    (n = 5)
Did not complete 1 PRO
assessment or did not receive
study treatment
   QLQ-C30              (n = 3)
   QLQ-LC13              (n = 3)
Did not complete 1 PRO
assessment or did not receive
study treatment
   QLQ-C30     (n = 2)
   QLQ-LC13     (n = 3)
281 randomly assigned to placebo-
combination group
(carboplatin plus paclitaxel, n = 167;
carboplatin plus nab-paclitaxel, n = 114)
278 randomly assigned to pembrolizumab-
combination group
(carboplatin plus paclitaxel, n = 169;
carboplatin plus nab-paclitaxel, n = 109)
Remained on treatment
 (n = 121)
Remained on treatment 
(n = 72)
Received assigned treatment 
(n = 278)
Received assigned treatment
 (n = 280)
Patients enrolled and randomly assigned 1:1 
(N = 559)
Patients screened 
 (n = 779)
Included in ITT population 
(n = 278)
Included in ITT population 
(n = 281)
Withdrew
Physician decision
Lost to follow-up
FIG 1. CONSORT diagram. Disposition of patients in the study. AE, adverse event; ITT, intent to treat; PD, progressive disease; PRO,
patient-reported outcome; QLC-C30, Quality of Life Questionnaire-Core 30; QLC-LC, Quality of Life Questionnaire-Lung Cancer Module 13.
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squares (LS) mean change from baseline with the 95%
CI and nominal P value. Time to deterioration in the
composite of cough, chest pain, or dyspnea was defined
as time to first onset of $ 10-point increase from
baseline with confirmation by a second adjacent $ 10-
point increase in any of the 3 symptoms under the
right-censoring rule. The nonparametric Kaplan-Meier
method was used to estimate the deterioration curve in
each group; a stratified Coxmodel with Efron’smethod of tie
handling was used to assess between-group differences.
Proportions of patients with improved, stable, and de-
teriorated scores at weeks 9 and 18 were summarized
based on multiple imputation for missing data with missing
at random assumption and then synthesized based on
Rubin’s rule. QLQ-C30/QLQ-LC13 scores were standard-
ized to a scale ranging from 0-100 by linear transformation.
For GHS/QoL and functional scales, higher scores indicate
a higher (better) level of function, whereas for the symptom
scales, higher scores indicate a higher (worse) severity of
symptoms.
RESULTS
Patients
Between August 19, 2016, and December 28, 2017, 559
patients were randomly assigned to pembrolizumab plus
chemotherapy (n = 278) or placebo plus chemotherapy
(n = 281; Fig 1). As of the data cutoff (April 3, 2018),
median follow-up was 7.8 months (range, 0.1-19.1
months). As reported previously, baseline characteristics
were similar between groups.2
With the exception of 1 patient in the placebo-combination
group, all enrolled patients received $ 1 dose of assigned
study treatment. Among these, the PRO analysis population
comprised 554 patients who completed $ 1 QLQ-C30
assessment and 553 patients who completed $ 1 QLQ-
LC13 assessment. Compliance rates were similar between
groups at baseline and weeks 9 and 18, and remained high
at both time points (Table 1). Completion rates for the QLQ-
C30 and QLQ-LC13 were high at baseline (. 90%) for both
groups (Table 1). At week 9, completion rates were 67.8%
and 71.6%, respectively, for the QLQ-C30 and 68.0% and
70.9%, respectively, for the QLQ-LC13. At week 18,
completion rates were 69.2% and 58.3% for the QLQ-C30,
and 69.5% and 58.3% for the QLQ-LC13 (Table 1). The
decline in completion rates at week 18 was associated with
an increase in the number of patients who discontinued
because of an AE, physician decision, disease progression,
study withdrawal, or death, or who had no scheduled visit.
Between-group differences at week 18 were mainly
attributed to an increase in the number of patients in the
placebo-combination group who were missing an HRQoL
instrument due to disease progression versus the
pembrolizumab-combination group (QLQ-C30: 4.0%, 11/
276 v 17.3%, 48/278; QLQ-LC13: 3.6%, 10/275 v 17.3%,
48/278).
TABLE 1. Completion and Compliance Rates for PRO Instruments
Patients Pembrolizumab-Combination Placebo-Combination
QLQ-C30
No.* 276 278
Baseline 254 (92.0) 264 (95.0)
Week 3
Completion 228 (82.6) 237 (85.3)
Compliance 228/265 (86.0) 237/266 (89.1)
Week 6
Completion 226 (81.9) 204 (73.4)
Compliance 226/253 (89.3) 204/251 (81.3)
Week 9
Completion 187 (67.8) 199 (71.6)
Compliance 187/233 (80.3) 199/225 (88.4)
Week 12
Completion 194 (70.3) 177 (63.7)
Compliance 194/227 (85.5) 177/224 (79.0)
Week 15
Completion 191 (69.2) 165 (59.4)
Compliance 191/224 (85.3) 165/201 (82.1)
Week 18
Completion 191 (69.2) 162 (58.3)
Compliance 191/217 (88.0) 162/187 (86.6)
QLQ-LC13
No.* 275 278
Baseline 252 (91.6) 263 (94.6)
Week 3
Completion 227 (82.5) 237 (85.3)
Compliance 227/265 (85.7) 237/266 (89.1)
Week 6
Completion 226 (82.2) 204 (73.4)
Compliance 226/253 (89.3) 204/251 (81.3)
Week 9
Completion 187 (68.0) 197 (70.9)
Compliance 187/233 (80.3) 197/225 (87.6)
Week 12
Completion 192 (69.8) 175 (62.9)
Compliance 192/227 (84.6) 175/224 (78.1)
Week 15
Completion 191 (69.5) 164 (59.0)
Compliance 191/224 (85.3) 164/201 (81.6)
Week 18
Completion 191 (69.5) 162 (58.3)
Compliance 191/217 (88.0) 162/187 (86.6)
NOTE. Data presented asNo. (%) unless otherwise indicated. Compliance rate was
defined as the percentage of patients who completed the PRO questionnaire among
those who were expected to complete the instrument at each time point (eg, those
who had not discontinued study treatment). Completion rate was defined as the
proportion of patients in the analysis population at each time point who completed
$ 1 assessment.
Abbreviations: PRO, patient-reported outcome; QLQ-C30, Quality of Life
Questionnaire-Core 30; QLQ-LC13, Quality of Life Questionnaire-Lung Cancer
Module 13.
*The PRO analysis population included patients who completed $ 1 treatment
dose and $ 1 PRO assessment
4 © 2019 by American Society of Clinical Oncology
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Key PRO Endpoints
Baseline mean (SD) QLQ-C30 GHS/QoL scores were similar
between the pembrolizumab-combination group (63.9
[20.4]) and placebo-combination groups (62.7 [21.3]). For
the pembrolizumab-combination group, mean QLQ-C30
GHS/QoL scores were above baseline at all time points, with
the largest improvements starting at week 18. For the
placebo-combination group, mean QLQ-C30 GHS/QoL
scores were lower versus baseline at all assessments
through week 36 (Fig 2).
At week 9, LS mean (95% CI) QLQ-C30 GHS/QoL scores
were stable in the pembrolizumab-combination group
(increase of 1.8 points [20.9 to 4.4]) and the placebo-
combination group (decrease by 1.8 points [24.4 to 0.7]).
The LS mean difference in score between groups at week 9
was 3.6 points (95% CI, 0.3 to 6.9; P = .0337). At week 18,
the LS mean (95% CI) QLQ-C30 GHS/QoL score was im-
proved from baseline in the pembrolizumab-combination
group (increase of 4.3 points [1.7 to 6.9]), whereas it was
stable in the placebo-combination group (decrease by 0.6
TABLE 2. Mean Changes From Baseline in QLQ-C30 GHS/QoL Score
Time Point
Pembrolizumab-Combination
(n = 276)
Placebo-Combination
(n = 278) P
Baseline
Completed questionnaire, No. 254 264
Mean score (SD) 63.9 (20.4) 62.7 (21.3)
Week 9
Completed questionnaire, No. 187 199
Mean score (SD) 66.0 (18.5) 62.1 (19.6)
Change from baseline*
Included in analysis, No. 276 278
LS mean score (95% CI) 1.8 (20.9 to 4.4) 21.8 (24.4 to 0.7)
Difference in LS mean (95% CI) 3.6 (0.3 to 6.9) P = .0337†
Week 18
Completed questionnaire, No. 191 162
Mean score (SD) 68.9 (19.3) 65.2 (17.1)
Change from baseline*
Included in analysis, No. 276 278
LS mean score (95% CI) 4.3 (1.7 to 6.9) 20.6 (23.3 to 2.2)
Difference in LS mean (95% CI) 4.9 (1.4 to 8.3) P = .0060†
Abbreviations: GHS/QoL, global health status/quality of life; LS, least squares; QLQ-C30, Quality of Life Questionnaire-Core 30; SD, standard
deviation.
*Based on a constrained longitudinal data analysis model with QLQ-C30 GHS/QoL scores as the response variable and treatment by study visit
interaction and randomization stratification factors as covariates.
†P values are 2 sided and nominal.
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points [23.3 to 2.2]). The LS mean difference in score
between groups at week 18 was 4.9 points (95% CI, 1.4 to
8.3; P = .0060; Table 2).
Eighty-one patients (29.3%) in the pembrolizumab-
combination group and 94 patients (33.8%) in the
placebo-combination group experienced deterioration in
the composite endpoint of cough, chest pain, or dyspnea.
Median time to deterioration for these symptoms was not
reached in either group (HR, 0.79; 95% CI, 0.58 to 1.06;
P = .125; Fig 3).
Supportive PRO Endpoints
The EORTC QLQ-C30 instrument includes 5 functional
domains (physical, role, emotional, cognitive, and social)
that are used to assess HRQoL in patients with cancer.
Change from baseline scores was numerically superior for
the pembrolizumab-combination group versus the
placebo-combination group across all functional scales at
weeks 9 and 18 (Figs 4A and 4B). For the pembrolizumab-
combination group, there were minimal changes from
baseline in physical, cognitive, role, and social function
scales at weeks 9 and 18, and improvements occurred in
emotional functioning score at both time points. In the
placebo-combination group at weeks 9 and 18, scores
declined from baseline for physical and role functioning,
there were minimal changes for cognitive and social
functioning, and improvements occurred for emotional
functioning (Figs 4A and 4B).
The EORTC QLQ-C30 instrument also includes 3 symp-
tom scales (fatigue, pain, and nausea/vomiting) and 6
single items assessing other symptoms common among
patients with cancer. Both treatment groups were im-
proved (lower scores) in most of the scales at week 9
(during taxane therapy), with further improvements at
week 18 (after taxane therapy). There were increases in
symptoms of fatigue, nausea/vomiting, and diarrhea at
week 9 for both treatment groups, and an increase in
diarrhea symptoms at week 18 for the pembrolizumab-
combination group. At both time points, the pembrolizumab-
combination group was numerically superior in fatigue, pain,
dyspnea, and insomnia, whereas the placebo-combination
group was numerically superior in the scales of nausea/
vomiting, appetite loss, constipation, and diarrhea (Figs 4C
and 4D).
Fewer patients in the pembrolizumab-combination group
reported a deterioration in GHS/QoL status versus the
placebo-combination group (week 9: 26.1% v 29.5%;
week 18: 22.8% v 31.3%). More patients in the
pembrolizumab-combination group reported an im-
proved GHS/QoL status versus the placebo-combination
group (week 9: 30.4% v 24.5%; week 18: 36.2% v
27.7%; Fig 5). There were fewer patients with a de-
terioration in physical functioning in the pembrolizumab-
combination group compared with the placebo-combination
group (week 9: 29.7% v35.3%;week 18: 26.1% v. 37.4%). At
weeks 9 and 18, the percentage of patients with improved/
stable scores across all functional scales was greater in the
pembrolizumab-combination group versus the placebo-
combination group. There were limited differences in dis-
tribution of improved, stable, and deteriorated scores on the
symptom scales at week 9 between the pembrolizumab-
combination and placebo-combination groups. More pa-
tients in the pembrolizumab-combination group versus
patients in the placebo-combination group had improved
symptom scale scores for fatigue (week 9, 37.0 v 33.1;
week 18, 46.0% v 37.1%), nausea and vomiting (week 9,
14.9 v 12.2; week 18, 16.3% v 13.3%), pain (week
9, 39.1 v 36.3; week 18, 40.2% v 35.3%), dyspnea (week
9, 35.5 v 27.3; week 18, 41.3% v 28.8%), and insomnia
(week 9, 34.1 v 32.4; week 18, 34.4% vs 31.7%). In
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contrast, the proportion of patients in the pembrolizumab-
combination group with deteriorated status was greater for
constipation (week 9, 23.2% v 20.1%; week 18, 19.6% v
19.1%) and diarrhea (week 9, 24.3% v 19.4%; week 18,
18.5% v 12.6%; Fig 5).
Analysis of the effect of disease progression on changes
from baseline in QLQ-C30 GHS/QoL score showed that
among patients with disease progression there were small
declines in GHS/QoL in both treatment arms at weeks 9 and
18 (Data Supplement). Among patients without disease
progression, GHS/QoL improved in the pembrolizumab-
combination arm and declined in the chemotherapy arm
at week 9, and at week 18 was further improved in the
pembrolizumab-combination arm, but was little changed
from baseline in the chemotherapy arm.
DISCUSSION
Pembrolizumab plus carboplatin and paclitaxel/nab-
paclitaxel maintained or improved HRQoL versus baseline
in patients with previously untreated metastatic squamous
NSCLC, whereas placebo plus carboplatin and paclitaxel/
nab-paclitaxel led to declines in HRQoL. Baseline QLQ-
C30 GHS/QoL scores were approximately 63 in both
treatment groups, which is higher (better) than EORTC
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FIG 4. Changes from baseline in Quality of Life Questionnaire-Core 30 (QLQ-C30) global health status/quality of life (GHS/QoL) and functional scale
scores at (A) week 9 and (B) week 18, and QLQ-C30 symptom subscale scores at (C) week 9 and (D) week 18. Higher functional scale scores represent
better functioning, whereas higher symptom subscale scores indicate more symptoms; higher GHS/QoL represents better health status/QoL.
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GHS/QoL reference values for patients with advanced lung
cancer before treatment (mean [SD], 54.7 [23.8]).12
Pembrolizumab-combination therapy improved HRQoL
versus placebo-combination therapy at week 18, based
on a between-group difference in LS mean scores of 4.9
(95% CI, 1.4 to 8.3; P = .0060). This difference is clin-
ically meaningful, as supported by the GHS/QoL re-
sponder analysis: a higher percentage of patients in the
pembrolizumab-combination group were classified as im-
proved (36.2% v 27.7%) and fewer were classified as
deteriorated (22.8% v 31.3%) at week 18 versus the
placebo-combination group. Week 9 between-group
differences (ie, during platinum-taxane therapy) fa-
vored the pembrolizumab-combination group versus
the placebo-combination group, but were smaller in
magnitude than those at week 18 (occurring after platinum-
taxane therapy). Specifically, more patients in the
pembrolizumab-combination group were classified as im-
proved for GHS/QoL and fewer were classified as de-
teriorated at week 9.
At the data cutoff (median follow-up, 7.8 months), ap-
proximately one third of patients had experienced de-
terioration in the composite endpoint of cough, chest pain,
or dyspnea; therefore, median time to deterioration had not
been reached in either group. Although the 95% CI for the
HR for time to deterioration in these symptoms contained 1,
these results support a trend of a delay in deterioration in
the pembrolizumab-combination group (HR, 0.79; 95% CI,
0.58 to 1.06; P = .125). These outcomes are clinically
meaningful in the context of demographic/clinical
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FIG 5. Proportions of patients with improved, stable, and deteriorated (A) Quality of Life Questionnaire-Core 30 global health status/quality of life (GHS/QoL)
and functional scale scores, and (B) symptom scale scores at weeks 9 and 18.
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characteristics of the KEYNOTE-407 study population,2
most of whom were current/former smokers, $ 65 years
of age, with an Eastern Cooperative Oncology Group per-
formance status of 1.
HRQoL results favoring the pembrolizumab-combination
group at week 18 were supported by trends in the EORTC
functional scales, which favored the pembrolizumab-
combination group across all scales at weeks 9 and 18.
The largest differences occurred in physical functioning
(abilities essential for maintaining independence) and role
functioning (abilities for work/leisure). Improvements in
physical and role functioning are relevant, given the an-
ticipated continued increase in cancer survivorship13,14;
treatment regimens may differentially affect patient func-
tioning, and physical and role functional status is likely to
affect HRQoL. The symptom scale results include trends
favoring each treatment group. The pembrolizumab-
combination group had better (lower score) symptom
scores for fatigue, pain, dyspnea, and insomnia versus the
placebo-combination group. However, these were offset by
better (lower scores) for GI or related symptoms (nausea/
vomiting, diarrhea, constipation, and appetite loss) for the
placebo-combination group. These findings are consistent
with the incidence of these AEs in the primary assessment
of efficacy, with the exception that decreased appetite oc-
curred more frequently in the placebo-combination group.2
Potentially, differences in frequency, duration, and/or se-
verity of such events may have contributed to this difference.
PROs from KEYNOTE-407 are consistent with other studies
demonstrating a benefit of pembrolizumab on QoL. Pem-
brolizumab monotherapy improved or maintained HRQoL
and delayed deterioration versus platinum-based chemo-
therapy in patients with stage IV NSCLC in the KEYNOTE-
024 study.6 Similarly, addition of pembrolizumab to
pemetrexed-platinum chemotherapy maintained GHS/QoL
relative to baseline, with improved GHS/QoL over placebo
plus pemetrexed-platinum chemotherapy at week 21 for
patients with nonsquamous NSCLC in the KEYNOTE-189
study.15 Although cross-trial comparisons are challenging,
the magnitude of improvement in HRQoL in KEYNOTE-407
appeared somewhat smaller than in KEYNOTE-024, but
remarkably consistent with KEYNOTE-189. In KEYNOTE-
407 and KEYNOTE-189, between-group differences in
GHS/QoL scores for the pembrolizumab-combination
therapies versus placebo-combination therapies were
similar at each time point (difference in LS mean scores:
3.6 for week 9 v 3.6 for week 12; 4.9 for week 18 v 5.3 for
week 21). Moreover, median time to deterioration was not
reached in either trial for the pembrolizumab-combination
therapies (HR [95% CI]: KEYNOTE-407, 0.79 [0.58 to
1.06]; KEYNOTE-189: 0.81 [0.60 to 1.09]). Importantly, in
this study, addition of pembrolizumab to chemotherapy
improved PROs, even in the context of the toxicity typically
associated with platinum-taxane therapy.
The main limitation of this study was the limited follow-up
period in assessing PROs. The limited follow-up was based,
in part, on the unblinding of the study at the second interim
analysis (following the recommendation of the external data
safety and monitoring board). Another limitation was the
decreasing PRO completion rates with increasing follow-up
and the moderate difference in completion rates between
groups owing to disease progression in the placebo-
combination group. In addition, the PRO change scores
reported here may not be generalizable to populations with
different baseline PRO values. A strength of this study was
the double-blind design, which reduced bias in PRO re-
sponses relative to an open-label study design.
In conclusion, pembrolizumab plus carboplatin and pac-
litaxel/nab-paclitaxel maintained or improved HRQoL
compared with baseline and improved HRQoL compared
with placebo plus carboplatin and paclitaxel/nab-paclitaxel
at week 18, as assessed by the EORTC QLQ-C30 and QLQ-
LC13 instruments. These HRQoL findings, along with the
improved efficacy (including OS benefit) of pembrolizumab
plus carboplatin and paclitaxel/nab-paclitaxel, support its
use as a first-line treatment of metastatic squamous
NSCLC, regardless of PD-L1 expression.
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